Anifrolumab (Saphnelo®). HTA ID: 23027

Assessment Status Full HTA submission received from Applicant
HTA ID 23027
Drug Anifrolumab
Brand Saphnelo®
Indication Anifrolumab (Saphnelo®) is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
Assessment Process
Rapid review commissioned 19/05/2023
Rapid review completed 14/06/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of anifrolumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
Full pharmacoeconomic assessment commissioned by HSE 05/07/2023
Pre-submission consultation with Applicant 14/08/2023
Full submission received from Applicant 30/05/2024

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.